Page 112 - ar2013

110 HAW PAR CORPORATION LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2013
29. SIGNIFICANT SUBSIDIARIES AND ASSOCIATED COMPANIES (continued)
Name of Company
Country of
incorporation Principal activities
Effective equity
interest held
by Group
2013
%
2012
%
* Haw Par Brothers International
(H.K.) Limited ++
Hong Kong Investment holding and
licensing of “Kwan Loong”
trademark
100.0 100.0
Haw Par Hong Kong Limited ++ Hong Kong Investment holding 100.0 100.0
Haw Par Management Services
Pte. Ltd.
Singapore Provision of management
support services
100.0 100.0
UIC Technologies Pte Ltd Singapore Investment holding 40.0 40.0
* Hua Han Bio-Pharmaceutical
Holdings Limited #
Cayman Islands Investment holding 15.2 16.4
Notes
(i) Companies indicated with a (*) are indirectly held by Haw Par Corporation Limited.
(ii) Companies indicated with a (+) are audited by PricewaterhouseCoopers member frms outside Singapore.
(iii) Companies indicated with a (++) are audited by other frms. These foreign-incorporated companies are
not considered as signifcant foreign-incorporated subsidiaries under the Singapore Exchange Securities
Trading Limited - Listing Rules. Accordingly, Rule 716 of the Listing Manual has been complied with.
(iv) The company indicated with a (#) is listed on an overseas stock exchange and audited by other frm of
auditors. Its fnancial year end is 30 June. The Group has equity accounted for the proft of its associated
company from 1 January 2013 to 30 June 2013 based on its audited accounts, and unaudited six months
results to 31 December 2013 as announced on the overseas stock exchange.
(v) The fnancial year-end for Haw Par India Private Limited (“HPI”) is 31 March as required by the laws of
its country of incorporation. The consolidated fnancial statements incorporated the unaudited results of
HPI from 1 January to 31 December.
(vi) All the above subsidiaries and associated companies operate in their respective countries of incorporation
except Hua Han Bio-Pharmaceutical Holdings Limited which operates mainly in the People’s Republic
of China.